Jennifer Specht, MD
![](https://education.binayfoundation.org/sites/default/files/styles/faculty_photo/public/JenniferSpecht.jpg?itok=_c6A-6Vb&c=ce8a50d810f3b789c8691b479fe9d56a)
Dr. Jennifer Specht is a medical oncologist specializing in the care of patients with breast cancer. She is the Clinical Research Director for the breast oncology program at UW. Her research interests include molecular imaging with FDG PET and DCE-MRI to understand in vivo biology of locally-advanced and inflammatory breast cancer and use of FDG PET to assess response to therapy in bone-dominant metastatic breast cancer. She is Co-Chair of ECOG-ACRIN FEATURE trial which is evaluating performance of serial FDG PET/CT to predict progression free survival in patients with breast cancer bone metastasis. She also conducts research into immunotherapeutic approaches for treatment of breast cancer with chimeric antigen receptor (CAR) T cell therapies. She is co-chair of BMT CTN Cellular Therapy for Solid Tumors SOSS Committee. She serves as breast liaison to Fred Hutch Integrated Immunotherapy Program, serve on IIRC clinical trials advisory committee, and serves as PI on cellular immunotherapy trials in the Bezos Immunotherapy Clinic.
Financial relationships
-
Attribution:SelfType of financial relationship:OtherIneligible company:A2 BiotherapeuticsTopic:Investigator Meeting ParticipantDate added:10/19/2021Date updated:02/27/2024Relationship end date:09/15/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:GE HealthcareTopic:Consultant/Advisory BoardDate added:11/28/2022Date updated:02/27/2024Relationship end date:12/31/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:GSKTopic:Advisory BoardDate added:11/28/2022Date updated:02/27/2024Relationship end date:12/28/2021
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Sensei BiotherapeuticsTopic:Clinical Advisory BoardDate added:11/28/2022Date updated:02/27/2024Relationship end date:06/03/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Volastra TherapeuticsTopic:ConsultantDate added:11/28/2022Date updated:02/27/2024Relationship end date:06/04/2022
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:Seattle GeneticsTopic:Institutional Research FundingDate added:11/28/2022Date updated:02/27/2024Relationship end date:11/01/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:PfizerTopic:Institutional Research FundingDate added:11/28/2022Date updated:02/27/2024Relationship end date:02/28/2022
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:MerckTopic:Institutional Research GrantDate added:11/28/2022Date updated:02/27/2024Relationship end date:09/01/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:XencorTopic:Institutional Research GrantDate added:11/28/2022Date updated:02/27/2024Relationship end date:02/29/2024
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:GenentechTopic:Institutional Research GrantDate added:11/28/2022Date updated:02/27/2024Relationship end date:05/13/2025